University of Turku has awarded Title of Docent to Dr. Ubaid Ullah Kalim
The University of Turku (Department of Life Technologies) has awarded the Title of Docent (Adjunct Professor) in molecular cell biology to Senior Research Fellow, Dr. Ubaid Ullah Kalim.
After PhD in 2012 from Jawaharlal Nehru University, New Delhi in the field of Immunology he has carried out postdoctoral research in the laboratory of Riitta Lahesmaa in Turku Bioscience Centre. His research focuses on epigenetic regulation of T cell activation and differentiation and molecular mechanisms of autoimmune disorders
-Over 90% disease associated SNPs lie in the noncoding regulatory region. Understanding the functional impact of the noncoding genome in health and disease may hold potential for novel therapies against human diseases, says Ubaid.
Recent Posts
- Dissertation Defence: Eleftheria MaranouMSc Eleftheria Maranou, from affiliated MIORG group, succesfully defended the dissertation in Immunology titled “The Achilles’ heel of Read moreSeptember 1, 2026
- Researchers discover molecular mechanism that helps aggressive colorectal cancer to spreadResearchers from the University of Turku in Finland, Turku Bioscience Centre and Gustave Roussy Institute Read moreAugust 25, 2026
- The Novo Nordisk Foundation has awarded funding of approximately one million euros to a research project led by Professor Jukka WestermarckThe Novo Nordisk Foundation has awarded funding of approximately one million euros to a research Read moreAugust 21, 2026
- Early-career researchers invited to BioCity Pre-Symposium on 26 August.Doctoral researchers at BioCity Turku are organising a pre-symposium on 26 August 2026, offering early-career Read moreApril 30, 2026
- 35th BioCity Symposium is arranged 27–28 August 2026.This year, BioCity Symposium is arranged on-site in Mauno Koivisto Centre, BioCity in 27–28 August Read moreApril 14, 2026
- Turku Protein Core Opens Two New PositionsTurku Protein Core (TuProtCore) is seeking to fill two roles: a Project Specialist in Service Read moreApril 7, 2026